Key Points
- Voss Capital purchased 104,183 shares of Rein Therapeutics (RNTX) on Nov. 14 at $1.22 per share for $127,103, raising its direct stake to 926,441 shares — a 12.67% increase in ownership.
- Voss has been actively accumulating stock in recent weeks, buying an additional 178,392 (Oct. 28), 97,482 (Oct. 27) and 30,176 (Oct. 24) shares — roughly 410,233 shares and about $550,600 total across these trades.
- Rein is a small-cap clinical-stage biotech (market cap ~$28.4M) with high institutional ownership (90.89%), a negative but slightly better-than-expected recent EPS, and a consensus analyst rating of "Hold" with a $8.00 target.
Rein Therapeutics Inc. (NASDAQ:RNTX - Get Free Report) major shareholder Voss Capital, Lp bought 104,183 shares of the firm's stock in a transaction on Friday, November 14th. The stock was acquired at an average cost of $1.22 per share, for a total transaction of $127,103.26. Following the completion of the purchase, the insider directly owned 926,441 shares in the company, valued at approximately $1,130,258.02. This represents a 12.67% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Voss Capital, Lp also recently made the following trade(s):
- On Tuesday, October 28th, Voss Capital, Lp purchased 178,392 shares of Rein Therapeutics stock. The stock was bought at an average cost of $1.39 per share, with a total value of $247,964.88.
- On Monday, October 27th, Voss Capital, Lp acquired 97,482 shares of Rein Therapeutics stock. The shares were bought at an average cost of $1.37 per share, for a total transaction of $133,550.34.
- On Friday, October 24th, Voss Capital, Lp bought 30,176 shares of Rein Therapeutics stock. The stock was bought at an average cost of $1.39 per share, with a total value of $41,944.64.
Rein Therapeutics Price Performance
NASDAQ RNTX opened at $1.22 on Wednesday. Rein Therapeutics Inc. has a 52 week low of $1.04 and a 52 week high of $3.50. The business's fifty day simple moving average is $1.31 and its 200-day simple moving average is $1.47. The firm has a market cap of $28.43 million, a PE ratio of -0.46 and a beta of 1.15.
Rein Therapeutics (NASDAQ:RNTX - Get Free Report) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.03. Research analysts expect that Rein Therapeutics Inc. will post -1.56 EPS for the current year.
Institutional Trading of Rein Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in RNTX. Susquehanna International Group LLP purchased a new stake in shares of Rein Therapeutics during the 3rd quarter worth approximately $35,000. Prosight Management LP boosted its stake in shares of Rein Therapeutics by 32.7% during the third quarter. Prosight Management LP now owns 567,898 shares of the company's stock valued at $650,000 after acquiring an additional 139,979 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Rein Therapeutics by 32.2% during the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company's stock worth $1,338,000 after buying an additional 284,300 shares in the last quarter. Gagnon Securities LLC raised its holdings in Rein Therapeutics by 218.8% in the 3rd quarter. Gagnon Securities LLC now owns 228,692 shares of the company's stock valued at $262,000 after acquiring an additional 156,947 shares during the last quarter. Finally, Gleason Group Inc. acquired a new position in Rein Therapeutics in the third quarter valued at $26,000. Institutional investors and hedge funds own 90.89% of the company's stock.
Analyst Ratings Changes
Several analysts have recently commented on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Rein Therapeutics in a research report on Wednesday, October 8th. Loop Capital set a $6.00 target price on Rein Therapeutics in a research note on Monday, November 3rd. HC Wainwright initiated coverage on Rein Therapeutics in a report on Monday, September 22nd. They issued a "buy" rating and a $10.00 price objective on the stock. Finally, Brookline Capital Management upgraded Rein Therapeutics from a "hold" rating to a "buy" rating in a research note on Monday, November 3rd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $8.00.
View Our Latest Research Report on Rein Therapeutics
Rein Therapeutics Company Profile
(
Get Free Report)
Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
